{"title":"Clinical Outcomes of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve.","authors":"Kota Komiyama, Kengo Tanabe, Eiji Taguchi, Tomohiro Sakamoto, Rine Nakanishi, Ryo Okubo, Akira Saito, Taku Asano, Akihiro Ikuta, Kazushige Kadota, Yui O Nozaki, Shinichiro Fujimoto","doi":"10.1536/ihj.24-534","DOIUrl":null,"url":null,"abstract":"<p><p>Coronary computed tomography angiography-derived fractional flow reserve (FFR<sub>CT</sub>) is useful for noninvasively detecting coronary artery disease. This procedure has been covered by health insurance reimbursement in the United Kingdom, the United States of America, and Japan. This is the first study to investigate the 1-year outcomes of the FFR<sub>CT</sub>, with management covered by health insurance from the DiscoverY of Novel Assessment Myocardial IsChemia by FFR<sub>CT</sub> (DYNAMIC-FFR<sub>CT</sub>) registry.In this multicenter DYNAMIC-FFR<sub>CT</sub> registry, 410 participants who underwent FFR<sub>CT</sub> analysis under health insurance reimbursement were prospectively enrolled at six Japanese sites between October 2019 and November 2021. In accordance with recent guidelines, all participants received appropriate revascularization and/or optimal medication therapy after FFR<sub>CT</sub>. The following clinical outcomes through the 1-year defined major adverse cardiovascular event (MACE) were investigated: all-cause death, cardiovascular events including non-fatal myocardial infarction, and unplanned hospitalization for acute coronary syndrome leading to revascularization.Of the six MACE cases, four (1.6%) occurred in participants with an FFR<sub>CT</sub> value ≤ 0.80, whereas two (1.3%) occurred in a participant with an FFR<sub>CT</sub> value > 0.80.This analytical study based on the DYNAMIC-FFR<sub>CT</sub> registry for cardiovascular conditions found no significant difference in 1-year MACE between FFR<sub>CT</sub>≤ 0.80 and > 0.80 following guideline-based therapy. The registry was started shortly after reimbursement and had limited statistical power and selection bias. Further studies with sufficient statistical power are required.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":"337-344"},"PeriodicalIF":1.2000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International heart journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1536/ihj.24-534","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Coronary computed tomography angiography-derived fractional flow reserve (FFRCT) is useful for noninvasively detecting coronary artery disease. This procedure has been covered by health insurance reimbursement in the United Kingdom, the United States of America, and Japan. This is the first study to investigate the 1-year outcomes of the FFRCT, with management covered by health insurance from the DiscoverY of Novel Assessment Myocardial IsChemia by FFRCT (DYNAMIC-FFRCT) registry.In this multicenter DYNAMIC-FFRCT registry, 410 participants who underwent FFRCT analysis under health insurance reimbursement were prospectively enrolled at six Japanese sites between October 2019 and November 2021. In accordance with recent guidelines, all participants received appropriate revascularization and/or optimal medication therapy after FFRCT. The following clinical outcomes through the 1-year defined major adverse cardiovascular event (MACE) were investigated: all-cause death, cardiovascular events including non-fatal myocardial infarction, and unplanned hospitalization for acute coronary syndrome leading to revascularization.Of the six MACE cases, four (1.6%) occurred in participants with an FFRCT value ≤ 0.80, whereas two (1.3%) occurred in a participant with an FFRCT value > 0.80.This analytical study based on the DYNAMIC-FFRCT registry for cardiovascular conditions found no significant difference in 1-year MACE between FFRCT≤ 0.80 and > 0.80 following guideline-based therapy. The registry was started shortly after reimbursement and had limited statistical power and selection bias. Further studies with sufficient statistical power are required.
期刊介绍:
Authors of research articles should disclose at the time of submission any financial arrangement they may have with a company whose product figures prominently in the submitted manuscript or with a company making a competing product. Such information will be held in confidence while the paper is under review and will not influence the editorial decision, but if the article is accepted for publication, the editors will usually discuss with the authors the manner in which such information is to be communicated to the reader.